Giussepe Yanez

Giussepe Yanez

Auto-generated profile, based on publicly available information

Giussepe Yanez

Duke University School of Medicine, Durham, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2025 in BMJ Open Quality
Verified
Journal Article
Open access
PDF file
DSDevika A Shenoy
Devika A Shenoy
KRKathryn Radulovacki
Kathryn Radulovacki
CZChristian Zirbes
Christian Zirbes
RSRachelle Shao
Rachelle Shao
GYGiussepe Yanez
Giussepe Yanez
ACAnthony A Catanzano
Anthony A Catanzano
Introduction: Paediatric patients with elevated healthcare needs have limited access to care, contributing to insufficient preventive services. Social drivers of health (SDOH), such as inadequate nutrition and poor community support, contribute substantially to paediatric health. In order to promote value-based healthcare, specialty providers like orthopaedic surgeons can serve as an entry point to connect patients to SDOH and primary care resources. The purpose of this short report is to provide a framework for other institutions for an ongoing screening programme. Overview of programme: Informed on prior initiatives, we designed a systematic screening programme for SDOH, obesity (via body mass index (BMI)) and primary care access in a paediatric orthopaedics clinic, for English-speaking and Spanish-speaking patients <18 years old. We record age, sex, race/ethnicity, language, orthopaedic condition, Area Deprivation Index and Childhood Opportunity Index from the electronic record previsit. BMI ≥95th percentile triggers referral to a paediatric obesity management programme. An institutional SDOH screen detects financial, food, transportation, housing and utility needs. A positive screen triggers a referral to institution and state-specific resources. A five-question Primary Care Access Screen identifies gaps in primary care access. A positive screen triggers an internal referral to paediatric primary care. Patients are flagged before visits, and screening results are reviewed. Students place referrals for positive screens, finalised by providers. Follow-up occurs at 6 weeks. Data collection: We assess screen positivity, referral uptake and completed appointments for all patients at 6 weeks.

9 April 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
DSDevika A. Shenoy
Devika A. Shenoy
AHAnna Hung
Anna Hung
ESElizabeth Sachs
Elizabeth Sachs
GYGiussepe Yanez
Giussepe Yanez
EPEmily Peairs
Emily Peairs
CSCaroline E. Sloan
Caroline E. Sloan
PURPOSE: Approximately three quarters of patients with sarcoma report financial toxicity, defined as the psychosocial and economic burden of cancer care. The Comprehensive Score for Financial Toxicity (COST) is a screening questionnaire validated in patients with cancer. However, its use is not widespread in sarcoma care, likely in part due to its complexity. This study aimed to characterize financial toxicity in patients with sarcoma and evaluate whether shorter screening tools can identify high-risk patients. METHODS: We conducted a survey and retrospective cohort study of patients treated for sarcoma at a large, academic sarcoma center in 2016-2024. Patients completed the COST questionnaire (11 graded questions, each scored on a five-point Likert scale from 0 to 4) and the shorter, four-question Worry about Affording Healthcare Scale (WAHS). We obtained clinical information from the electronic health record. We used descriptive statistics to summarize responses to COST, Pearson's correlation coefficient to assess the association between WAHS and COST, and stepwise Spearman correlations to evaluate whether an abbreviated (1-4 question) version of COST correlated highly with total COST score. RESULTS: Among 205 participants, the mean COST score was 20/44 (standard deviation = 6; lower scores indicate greater financial toxicity). Respondents worried most about job loss (mean COST: 0.99) and family finances (mean COST: 1.11). WAHS was weakly correlated with COST (r = 0.47, P < .01). A four-item abbreviated COST tool was strongly correlated with the total COST (ρ = 0.906, P < .0001) and demonstrated high sensitivity (96%) and moderate specificity (75%). CONCLUSION: An abbreviated four-item COST tool could act as a clinically feasible, accurate screening tool after external validation. Routine financial toxicity screening could facilitate timely detection and referral to essential financial navigation resources.

23 July 2026 in Global Surgical Education - Journal of the Association for Surgical Education
Verified
Journal Article
Closed access
PDF file
GYGiussepe Yanez
Giussepe Yanez
ASAlexandria L. Soto
Alexandria L. Soto
RZRebecca A. Zasloff
Rebecca A. Zasloff
MMMichael Mensah-Mamfo
Michael Mensah-Mamfo
AOAkosua D. Odei
Akosua D. Odei
CVCory J. Vatsaas
Cory J. Vatsaas